Update: February 2024
|
ACH |
air change per hour |
|
AFB |
acid-fast bacilli |
| ALT | alanine aminotransferase |
|
Am |
amikacin |
|
Amx/Clv |
amoxicillin/clavulanic acid |
|
ART |
antiretroviral therapy |
|
ARV |
antiretroviral |
| AST | aspartate aminotransferase |
|
BCG |
bacillus Calmette-Guérin |
|
Bdq |
bedaquiline |
| BPNS | brief peripheral neuropathy screen |
| BSC | biosafety cabinet |
|
CDC |
Centers for Disease Control and Prevention |
|
Cfz |
clofazimine |
|
CMX |
cotrimoxazole |
| CNS | central nervous system |
|
CPC |
cetylpyridinum chloride |
|
CPT |
cotrimoxazole preventive therapy |
|
CrCl |
creatinine clearance |
|
Cs |
cycloserine |
| CSF | cerebrospinal fuid |
|
CXR |
chest x-ray |
| Dlm | delamanid |
|
DOT |
directly observed therapy |
|
DR |
drug resistance |
|
DR-TB |
drug-resistant tuberculosis |
| DS-TB | drug-susceptible tuberculosis |
|
DST |
drug susceptibility test |
|
E |
ethambutol |
|
ECG |
electrocardiogram |
| e.g. | for example |
|
EPTB |
extrapulmonary tuberculosis |
|
Eto |
ethionamide |
|
FDC |
fixed-dose combination |
|
FNA |
fine needle aspiration |
|
FQ(s) |
fluoroquinolone(s) |
| gDST | genotypic drug susceptibility test |
| GUV | germicidal ultraviolets |
|
H |
isoniazid (standard dose) |
| HbA1c | glycated haemoglobin |
| HEPA | high efficiency particulate air |
| Hh | isoniazid (high dose) |
|
HIV |
human immunodeficiency virus |
|
HPF |
high-power field |
| Hr | isoniazid resistance |
| Hr-TB | isoniazid resistant tuberculosis |
| i.e. | that is |
| IGRA |
interferon gamma release assay |
|
IM |
intramuscular |
|
Imp/Cln |
imipenem/cilastatin |
| INH | isoniazid |
| INI | integrase inhibitor |
| IPC | infection prevention and control |
|
IRIS |
immune reconstitution inflammatory syndrome |
| IV | intravenous |
| LF-LAM | lateral flow urine lipoarabinomannan assay |
|
LFT |
liver function test |
|
Lfx |
levofloxacin |
|
LPA |
line probe assay |
| LTBI | latent tuberculosis infection |
| LTR | long treatment regimen |
|
Lzd |
linezolid |
|
MDR |
multidrug resistance |
|
MDR-TB |
multidrug-resistant tuberculosis |
|
Mfx |
moxifloxacin (standard dose) |
|
Mfxh |
moxifloxacin (high dose) |
|
Mpm |
meropenem |
| MSF | Médecins Sans Frontières |
| MTB | Mycobacterium tuberculosis |
| NAAT | nucleic acid amplification test |
| NGS | next generation sequencing |
|
NNRTI |
non-nucleoside reverse transcriptase inhibitor |
|
NRTI |
nucleoside reverse transcriptase inhibitor |
| P | rifapentine |
| Pa | pretomanid |
|
PAS |
para-aminosalicylic acid |
|
PCP |
pneumocystosis |
|
PCR |
polymerase chain reaction |
| pDST | phenotypic drug susceptibility test |
|
PI |
protease inhibitor |
| PIH | Partners In Health |
|
PO |
orally (per os) |
| PTB | pulmonary tuberculosis |
|
Pto |
prothionamide |
|
R |
rifampicin |
|
Rfb |
rifabutin |
| RIF (or Rif) | rifampicin |
| RMT | rapid molecular test |
|
RR |
rifampicin resistance |
|
S |
streptomycin |
| SAT | self-administered treatment |
| STR | short treatment regimen |
|
TB |
tuberculosis |
| tNGS | targeted next generation sequencing |
| Trd | terizidone |
|
TSH |
thyroid-stimulating hormone |
|
TST |
tuberculin skin test |
| ULN | upper limit of normal |
| VOT | video-observed therapy |
| VVS | ventilated workstation |
| WGS | whole genome sequencing |
|
WHO |
World Health Organization |
|
XDR |
extensive drug resistance |
|
XDR-TB |
extensively drug-resistant tuberculosis |
|
Z |
pyrazinamide |